drugset / Trial / NCT03314636
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Phase 2
Active not recruiting
53 enrolled
Oslo University Hospital
Nordic Myeloma Study Group · collab
NaSingle-groupOpen-labelTreatment
Summary
A PET-CT will be performed on patients with myeloma after a standard first-line treatment. The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd), before a new PET-CT will be performed.
Timeline
- Start
- 2018-03-16
- Primary completion
- 2021-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | — |
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |